- Home
- EDTK vs PHIO Comparison
EDTK vs PHIO Comparison
Compare EDTK & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDTK | PHIO |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 12.3M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDTK | PHIO |
|---|---|---|
| Price | $0.90 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 12.9K | ★ 378.0K |
| Earning Date | 12-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $893,690.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $0.97 |
| 52 Week High | $1.20 | $9.79 |
Technical Indicators
Market Signals| Indicator | EDTK | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 34.73 |
| Support Level | $0.87 | $1.00 |
| Resistance Level | $0.91 | $1.18 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 47.46 | 22.22 |
Price Performance
Historical ComparisonAbout EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.